INTRODUCTION
The diagnosis and staging of Chronic Kidney Disease (CKD) based on estimates of GFR from plasma creatinine (cr) and cystatin C (cysC) concentrations represent a major step in the diagnosis of CKD and in following its course but has significant limitations. The main limitations of this methodology are its low discriminatory power in establishing the presence or absence of early CKD in individuals and its unsatisfactory performance in predicting the course of CKD.
The direction of Research in this field is currently towards identifying new biomarkers that either is superior indicators of GFR or indicate early injury of the renal tissue. The last group of biomarkers has the potential of leading to improved early detection of CKD (Ahmed et al, 2017) . CKD is an asymptomatic disease, tests for screening and early diagnoses are critical in nephrology. The tests that best detect abnormalities in kidney function and defined stages of CKD are those that measure GFR (Taal, 2011) . Epidemiology: Although, several epidemiologic studies were conducted to estimate the disease burden in different parts of these countries, the largest being the EGIPT-CKD (Egypt Information, Prevention, and Treatment of CKD) Project. Preliminary data for about 1,000 participants showed the prevalence of proteinuria to be as high as 21%, including 3.9% with elevated serum cr levels (Barsoum, 2012) . Risk Factors: CKD is affected by various risk factors, including demographic variables (age, gender and ethnicity), hereditary factors, primary renal disease, cardiovascular disease and nephrotoxins act. (Taal, 2011; Parveen et al, 2016) . However, Abd ElHafeez et al, (2018) reported that the main risk factors of CKD in Africa is attributed to hypertension and diabetes. The poor data quality restricts the validity of the findings and draws attention to the importance of designing future robust studies.
Estimation of the GFR:
The GFR can be estimated from the plasma concentration of filtration markers (such as cr or urea) (Nankivell, 2001 and Burtis, 2012) . Although, estimating cr is not costly there are limitations of using cr in calculating GFR such as muscle mass, age, gender, ethnic race, and diet. Moreover, these factors result in a complication of its equations that calculate GFR. However, cr is not sensitive in CKD early stages. On the other hand, cysC is not affected by those factors mentioned above, so that, its equations that calculate GFR are simple. Moreover, cysC is sensitive in diagnoses early stages of CKD (Taal, 2011) . But in clinical practice, cysC is economically costly especially during a routine check-up in those living in areas where little access to primary health care is available (Filler, 2005) . Janice et al, (2017) reported that there is a good correlation between cr and cysC this fact gives the one an idea to propose a new simple model for calculating GFR in early stages in CKD the model used the predictive value of cysC from estimated cr. The receiver operating characteristic (ROC) curve: This test provides a way of assessing whether a particular type of test provides useful information, and can be used to compare two different tests and to select an optimal cut-off value for a test (Aviva, 2009) 
MATERIALS AND METHODS
The aim of this study was to assess the potential role of a three glomerular filtration rate (GFR) calculation equations in discriminating between stages of CKD in Sudanese patients.
Enrolment of Patients:
A total of Three hundred and seventy-five (375) (Levey et al., 2003 and KDOQI, 2008) . CKD subjects aged between 18-90 years were included in the study. Individuals with skeletal muscle atrophy, malnutrition, heart failure, ketoacidosis, hypothyroidism or hyperthyroidism, malignant tumor, and acute inflammatory conditions were excluded from this study.
Blood Sampling:
A sample of 5 ml venous blood was collected from each subject and drawn into a heparinized plasma vacationer. Blood is drawn into green top heparin tubes, inverted 8-10 times immediately after the blood sample has been taken. Centrifugation conditions: ≤1300 g for 10 minutes at 18-25°C then transferred into a plain container and stored at -20 degrees Celsius until analysis.
Laboratory Assessment:
Biochemical parameters analyzed were plasma cr and plasma cysC. cr was estimated by kinetic colorimetric compensated Jaffe method (Jaffe et al., 1986) , as reported by the manufacturer, ROCHE COBAS c311 clinical chemistry automated analyzer (Roche Diagnostics, Swiss), which was standardized to the spectrometry reference, and cysC was estimated by measured ELISA enzymatic activity measurements in the wavelength range between 400 and 750 nm using kinetic measurement methods.
(Convergys® EL-Reader 96X, US). (Png et al., 2011) .
GFR Estimates:
Patient samples were classified according to the proposed KDIGO classification of chronic kidney disease into 5 stages (Levey et al., 2011) . After the determination of plasma concentrations, glomerular filtration rate was estimated by using the following three equations: 1-GFR Statistical analysis was done using SPSS. Data were represented as mean ± standard deviation. One way anova test was used for comparison between the groups. The ability of the studied tests and formulae to discriminate stages of CKD was evaluated using the area under the ROC curve (AUC). The sensitivity, specificity, differential positive rate (DPR), Diagnostic accuracy (DA), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were calculated according to the following formulae: Sensitivity = a/(a+c) Specificity = d/(b+d) DPR = sensitivity + specificity -100 DA = a+d\a+b+c+d PPV = a/(a+b) NPV = c/(c+d) PLR = sensitivity /(1-specificity) NLR = (1-sensitivity) /specificity Where: a = true positive cases, c = false negative cases, d = true negative cases, b = false positive cases. Statistical significance was considered as p <0.001.
RESULTS
The aim of this study was to assess the potential role of a three GFR calculation equations in discriminating between stages of CKD in Sudanese patients. 
CKD prevalence in the study population:
Patient samples were classified according to the proposed KDIGO classification of chronic kidney disease (Levey et al., 2011) ; number of the patients with stage three had the highest percentage value 101 (26.9%) as presented in Table 2 and Figure 2 .
Overall, 58 (15.5%) of the patients had normal eGFR, whereas three-quarters of the analyzed subjects had CKD as the following: 66 (17.6%) had mild decrease excretory renal function (eGFR: 60-89 ml/min/1.73m
2 ), about 101 (26.9%) of the patients had a moderate decrease eGFR of 59-30 ml/min/1.73m 2 , and 81 (21.6%) showed severe decrease in eGFR (29-15 mL/min/1.73 m 2 ). And about fifth 69 (18.4%) of the patients had a substantially renal failure <15 mL/min/1.73m 2 (Table 2  and Figure1) . 
ROC analysis of the studied markers and their diagnostic criteria:
Discriminating between stage 1 and stage 2 of CKD: GFR cr-cysC: The discriminating ability of the studied markers, GFR crcysC in detecting early CKD was assessed by plotting the ROC curves, which were drawn by the sensitivity and (1-specificity) at different cut-off levels (Table 3 and Figure 2 .). The AUC was 0.983 indicating the success of using GFR cr-cysC as a diagnostic marker for stage 1 and stage 2 of CKD. The nearest point to the upper left corner of the Figure 2 represent the optimal threshold (90.15 mL/min/1.73 m 2 ), the sensitivity was (100 %), the specificity was (97.3 %) and the DA, positive and negative predictive values, and DPR were (98.65 %), (100 %) and (97%) respectively. As for the likelihood ratios (LR) positive and negative, the PLR was 37.04 and the NLR was zero (Table 3 ). The maximum detected DPR was at (0.973). Figure 2 Represent the ROC curve of GFR cr as a diagnostic marker for stage 1 and stage 2 of CKD population. The AUC was 0.77 indicating the validity of using GFR cr as a diagnostic marker for CKD. The nearest point to the upper left corner of the Figure 2 refers to the optimal curoff value (83.75 mL/min/1.73 m 2 , Table 3 ). The sensitivity, specificity, DA, DPR, PPV and NPV were (62.2 %), (83.8 %), (77.02 %), (0.459), (100%) and (97%) respectively. whereas the PLR was 3.84 and NLR was 0.45 (Table 3) .
GFR cr:

GFR cysC:
The AUC of GFR cysC 0.821, indicating the successes of using GFR cysC as a diagnostic marker for stage 1 and stage 2 of CKD (Figure 2) . The nearest point to the upper left corner refers to the optimal cut-off value (97.25 mL/min/1.73 m 2 ) and large AUC. The sensitivity, specificity, DA, DPR, positive and negative predictive values were (81.1 %), (73 %), (78 %), (0.541), (71%) and (96%) respectively whereas the PLR was 3.0 and NLR was 0.26 (Table 3) .
Discriminating between stage 2 and stage 3 of CKD: GFR cr-cysC:
After ROC curve analysis, we revealed the optimal cut-off value which is the nearest point to the upper left corner that satisfies maximum sensitivity and maximum specificity. For the GFR cr-cysC (Fig. 3 ) an optimum cut-off level of (59.75 mL/min/1.73 m 2 ) and AUC 0.98 at which the sensitivity was 97.1% and specificity 96.3%. DA, DPR, positive and negative predictive values were (96%), (0.935), (99 %), and (89%) respectively. As for the LR positive and negative, the PLR was 26.24 and the NLR was 33.21 (Table 3) .
GFR cr:
ROC analysis revealed an optimal cut-off value of (41.95 mL/min/1.73 m 2 ) at and AUC 0.81.7 which the sensitivity (85.7%) and specificity (69.5%) were obtained. The DA, DPR, PPV and NPV were (52%), (0.703), (100 %), and (38%) respectively whereas the PLR was 2.81 and NLR was 33.21 (Table 3 and Figure 3 ).
GFR cysC:
At (62.6 mL/min/1.73 m 2 ) as a cut-off value and AUC 0.889, the sensitivity was 88.6% and specificity was 81.7%. The DA, DPR, PPV and NPV were (93%), (0.703), (99 %), and (83%) respectively whereas the PLR was 4.84 and NLR was 0.14 (Table 3 and Figure 3) . Discriminating Between Stage 3 and Stage 4 of CKD: GFR cr-cysC: Figure 4 showed the AUC was 0.962 indicating the success of using GFR cr-cysC as a diagnostic marker for stage 3 and stage 4 of CKD. The nearest point to the upper left corner represents the optimal threshold (30.05 mL/min/1.73 m 2 ), the sensitivity was (96.5 %), the specificity was (98.4 %) and the DA, DPR, PPV and NPV values were (97%), (0.949), (95%), and (99%) respectively. As for the LR positive and negative, the PLR was 60.31 and the NLR was 0.04 (Table 3) . GFR cr: Figure 4 Represent the ROC curve of GFR cr as a diagnostic marker for stage 3 and stage 4 of CKD population. The AUC was 0.924 indicating the validity of using GFR cr as a diagnostic marker for CKD. The nearest point to the upper left corner refers to the optimal cut-off value (19.35 mL/min/1.73 m 2 , Table 3 ). The sensitivity, specificity, DA, DPR, PPV and NPV values were (96 %), (0.739), (92 %) and (99%) respectively. whereas the PLR was 8.61 and NLR was 0.18 (Table 3) .
The AUC of GFR cysC 0.667, indicating the successes of using GFR cysC as a diagnostic marker for stage 3 and stage 4 of CKD (Fig. 4) . The nearest point to the upper left corner refers to the optimal cut-off value (49.95 mL/min/1.73 m 2 ) . The sensitivity, specificity, DA, DPR, PPV and NPV values were (51.8%), (83.9%), (91%), (0.356), (95%) and (89%) respectively whereas the PLR was 3.22 and NLR was 0.57 (Table 3) .
Discriminating Between Stage 4 and Stage 5 of CKD: GFR cr-cysC:
ROC curve analysis for GFR cr-cysC revealed that, the optimal cutoff value which is the nearest point to the upper left corner that satisfies maximum sensitivity and maximum specificity for the stage 3 and stage 4 of CKD. (Figure 5 .), the optimum cutoff level was (14.6 mL/min/1.73 m 2 , Table 3 ) and AUC 0.987 at which the sensitivity was 97% and specificity 96%. DA, DPR, PPV and NPV values were (97%), (0.93), (92%) and (98%) respectively. As for the LR positive and negative, the PLR was 24.25 and the NLR was 0.03 (Table 3) .
GFR cr:
ROC analysis revealed an optimal cut-off value of (6.1 mL/min/1.73 m 2 , Table 3 ) and AUC 0.951 at which the sensitivity (84.8%) and specificity (92%) were obtained. The DA, DPR, PPV and NPV were (73%), (0.768), (50%) and (100%) respectively whereas the PLR was 10.6 and NLR was 0.17 (Fig. 5 ).
GFR cysC:
At (46.35 mL/min/1.73 m 2 ) as a cut off value and AUC 0.648, the sensitivity was 45.5% and specificity was 88%. The DA, DPR, PPV and NPV were (1%), (0.335), (1%) and (0.8%) respectively whereas the PLR was 3.79 and NLR was 0.62 (Table 3 and Figure 5 ). 
DISCUSSION
Recent reports have stressed the need for new kidney markers that can enhance the accuracy of CKD detection for that, in the current study we evaluated three methods used in diagnosing the CKD. From the above, it is clear that the three methods significantly can be used to calculate the optimal cut-off value including mean ± SD, discriminant score and the ROC method (Table 3 ). The GFRcrcysC method is the most accurate method within all stages with respect to the calculated DA and DPR. In addition, the ROC curve analysis is the only method can be used to evaluate a kidney marker as a whole according to its AUC (as shown in Table 3 and Figures 2, 3, 4 and 5) a finding that came in agreement with Jeffrey et al., (2015) , who reported that combined eGFRcr-cysC performs best across all patient types for predicting measured GFR in comparison to the studied cr and cysC equations. The predicted values of GFR based on separate GFRcysC and GFRcr equations was assessed with an evaluation of ROC curves, which are shown in Table 3 , Figure 2 and Figure  3 . The ROC curve using GFRcysC showed largest AUC values than that for GFRcr between stages 1 and 2 and between stage 2 and 3, this might reflect to some extent the GFRcysC preference over the GFRcr in this regard. On the other hand, the GFRcr showed in Table 3 , Figure 4 and Figure 5 showed that AUC values higher than that for GFRcysC between the stage3 and 4 and between stage 4 and 5, this might reflect to some extent the poor ability of the GFRcysC in discriminating end stages of CKD this was in line with, Torre, et al, (2016) who reported that the accuracies of eGFRcysC and eGFRcr-cysC are higher than eGFRcr in early stages, but is limited at end-stage of eGFRs.
